Clinical Trial Update: A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating oral recombinant salmon calcitonin (rsCT) to prevent postmenopausal osteoporosis in women with osteopenia; the trial is completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis

Drugs mentioned

• Oral recombinant salmon calcitonin (rsCT) (salmon calcitonin)

Snippet

Sponsor: Tarsa Therapeutics, Inc. | Conditions: Osteopenia | Phase 2 | Status: COMPLETED | Results posted: 2014-09-12